Patent · US Active

Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles

US10656162B2 · kind B2 · utility

0Cited by

0References

48Claims

0Family size

Assignee

Basilea Pharmaceutica AG · CH

Inventors

Heidi Lane · Biel-Benken, CH
Felix Bachmann · Basel, CH

Key dates

Filing date	May 22, 2018
Grant date	May 19, 2020
Priority date	—
Expiry date	May 22, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Use of glu-tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.